Serkan Dogan1, Kadri Guven2, Mehmet Celikbilek3, Kemal Deniz4, Berkay Saraymen5, Sebnem Gursoy2. 1. Department of Gastroenterology and Hepatology, Medical School, Erciyes University, Kayseri, Turkey. serkandogan77@yahoo.com. 2. Department of Gastroenterology and Hepatology, Medical School, Erciyes University, Kayseri, Turkey. 3. Department of Gastroenterology and Hepatology, Medical School, Bozok University, Yozgat, Turkey. 4. Department of Pathology, Medical School, Erciyes University, Kayseri, Turkey. 5. Department of Biochemistry, Medical School, Erciyes University, Kayseri, Turkey.
Abstract
BACKGROUND: Previous studies have suggested that adipokines play a role in inflammatory bowel disease by inducing proinflammatory cytokines, but it is uncertain whether visfatin is causally involved in ulcerative colitis (UC). We evaluated visfatin levels in patients who presented with UC flares before and after treatment. METHODS: In this cohort study, we assessed 31 patients with UC in the activation period and remission in the same patients after treatment, and a healthy control group, consisting of 29 persons, at a single academic medical centre between 2010 and 2013. Disease severity was evaluated clinically using Trulove and Witt's criteria. RESULTS: Serum visfatin levels did not vary according to the extent of disease and were significantly higher in patients in the activation period (7.77 ± 2.41 ng/ml) than in remission (6.18 ± 2.04 ng/ml) and the healthy controls (6.54 ± 2.20 ng/ml; P < 0.01 and < 0.05, respectively). In a comparison of patients in the inactive period with the control group, there was no statistically significant difference (P > 0.05). To assess activation of the disease, a visfatin cut-off point for active UC was determined as 6.40, with sensitivity, specificity, positive predictive value (PPV) and negative predictive values (NPV) of 72%, 52%, 66.7% (43.0-85.4) and 50.0% (29.1-70.9), respectively. CONCLUSIONS: The visfatin level was higher in the active group than in post-treatment remission and the healthy control group. Sensitivity and specificity were similar to other inflammatory markers for assessing clinical activity, which did not improve clinical outcomes in patients with acute respiratory distress syndrome (ARDS). These findings did not provide a rationale for assessment of UC activation.
BACKGROUND: Previous studies have suggested that adipokines play a role in inflammatory bowel disease by inducing proinflammatory cytokines, but it is uncertain whether visfatin is causally involved in ulcerative colitis (UC). We evaluated visfatin levels in patients who presented with UC flares before and after treatment. METHODS: In this cohort study, we assessed 31 patients with UC in the activation period and remission in the same patients after treatment, and a healthy control group, consisting of 29 persons, at a single academic medical centre between 2010 and 2013. Disease severity was evaluated clinically using Trulove and Witt's criteria. RESULTS: Serum visfatin levels did not vary according to the extent of disease and were significantly higher in patients in the activation period (7.77 ± 2.41 ng/ml) than in remission (6.18 ± 2.04 ng/ml) and the healthy controls (6.54 ± 2.20 ng/ml; P < 0.01 and < 0.05, respectively). In a comparison of patients in the inactive period with the control group, there was no statistically significant difference (P > 0.05). To assess activation of the disease, a visfatin cut-off point for active UC was determined as 6.40, with sensitivity, specificity, positive predictive value (PPV) and negative predictive values (NPV) of 72%, 52%, 66.7% (43.0-85.4) and 50.0% (29.1-70.9), respectively. CONCLUSIONS: The visfatin level was higher in the active group than in post-treatment remission and the healthy control group. Sensitivity and specificity were similar to other inflammatory markers for assessing clinical activity, which did not improve clinical outcomes in patients with acute respiratory distress syndrome (ARDS). These findings did not provide a rationale for assessment of UC activation.
Authors: Axel Dignass; Rami Eliakim; Fernando Magro; Christian Maaser; Yehuda Chowers; Karel Geboes; Gerassimos Mantzaris; Walter Reinisch; Jean-Frederic Colombel; Severine Vermeire; Simon Travis; James O Lindsay; Gert Van Assche Journal: J Crohns Colitis Date: 2012-10-03 Impact factor: 9.071
Authors: Marek Waluga; Marek Hartleb; Grzegorz Boryczka; Michał Kukla; Krystyna Zwirska-Korczala Journal: World J Gastroenterol Date: 2014-06-14 Impact factor: 5.742
Authors: Magdalena Olszanecka-Glinianowicz; Jerzy Chudek; Piotr Kocełak; Adam Szromek; Barbara Zahorska-Markiewicz Journal: Metabolism Date: 2010-07-02 Impact factor: 8.694
Authors: Alexander R Moschen; Arthur Kaser; Barbara Enrich; Birgit Mosheimer; Milan Theurl; Harald Niederegger; Herbert Tilg Journal: J Immunol Date: 2007-02-01 Impact factor: 5.422
Authors: S Lichtiger; D H Present; A Kornbluth; I Gelernt; J Bauer; G Galler; F Michelassi; S Hanauer Journal: N Engl J Med Date: 1994-06-30 Impact factor: 91.245
Authors: Luzia Valentini; Eva Katrin Wirth; Ulrich Schweizer; Susanne Hengstermann; Lennart Schaper; Thomas Koernicke; Ekkehart Dietz; Kristina Norman; Carsten Buning; Brigitte M Winklhofer-Roob; Herbert Lochs; Johann Ockenga Journal: Nutrition Date: 2008-10-11 Impact factor: 4.008
Authors: Song Hui Jia; Yue Li; Jean Parodo; Andras Kapus; Lingzhi Fan; Ori D Rotstein; John C Marshall Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: Jan Bilski; Agnieszka Mazur-Bialy; Dagmara Wojcik; Marcin Surmiak; Marcin Magierowski; Zbigniew Sliwowski; Robert Pajdo; Slawomir Kwiecien; Aleksandra Danielak; Agata Ptak-Belowska; Thomas Brzozowski Journal: Biomolecules Date: 2019-11-26
Authors: Eva Karaskova; Maria Velganova-Veghova; Milos Geryk; Hana Foltenova; Veronika Kucerova; David Karasek Journal: Int J Mol Sci Date: 2021-04-19 Impact factor: 5.923